Kimberly Westrich, MA, of the National Pharmaceutical Council, explained how she envisions value assessment tools to be used in the US health care system in coming years.
Kimberly Westrich, MA, chief strategic officer at the National Pharmaceutical Council (NPC), discussed the future of value assessment tools in the US health care system. In her role, she provides strategic guidance to NPC’s policy research and communications activities, leads several research initiatives across NPC’s portfolio, and mentors NPC researchers and fellows.
Transcript
How do you envision the future of value assessment tools in the US health care system? What trends do you expect to shape the field in coming years?
This brings to mind an interesting conversation that's been happening for a few years. I don't think it's going to be settled soon, but there's been ongoing conversations about whether or not we need a national value assessment, or health technology assessment, body here in the United States. Outside of the United States, there are many countries that have a single health technology assessment body, and that makes sense because, outside of the United States, there's often centralized health insurance provided by the government; of course, here in the United States, we've got a decentralized system.
That said, there are many people who think that it would still be useful to have a centralized health technology assessment body, and there's been recent conversations looking at CMS and some of the things that CMS is doing related to, for example, coverage with evidence development for Alzheimer's disease, or getting involved in Medicare drug price negotiation. There are people who think, "Well, CMS is already starting to do some things that seem to be consistent with value assessment, and should CMS be a value assessment body?" There's people on both sides of the issue, some people think that CMS should be leaning into that, some people say, "This is not a direction for CMS, it would be biting off more than it can chew, and if we did have a health assessment body here in the United States, it shouldn't be CMS."
We [Cencora] actually added some questions to our Managed Care Network survey this year to see if payers in the United States have an appetite for a national health assessment body, and, if so, what they might want that body to do. Surprisingly, 85% of payers were interested in having a national value assessment body. There was sort of a split between whether they wanted it to be government funded, that was about 50% of payers. Then, 40% were interested in a split between government and private funding so that you had funding coming from multiple sources; it wasn't beholden to just one part of the economy.
The interesting data was when we asked about what this value assessment body might do, 85% of the respondents were interested in having a value assessment body that looked at best practices and standards, really understanding, what does good value assessment look like? Seven out of 10 (this was a multiple response question) were interested in having a national HTA [health technology assessment] body that looked at quality value assessment reports that were conducted by others. For example, if ICER [the Institute for Clinical and Economic Review] does a value assessment report, this national assessment body could look at it and say whether or not it was of good quality. So, that was something that was very interesting to payers, as well. Then, a lower percentage, but still noteworthy, I think, closer to 6 in 10 were interested in a national assessment body that did conduct its own value assessment. So, there's most interest in what does good look like? Is this report an example of good? Then, still interest, but lesser interest, in conducting value assessments.
Still, when you step back and you look at all of that together, here, I think there is interest in getting more value assessment information by US payers, I don't think there's interest in prescriptive value assessment information, or something that says, "This is how this should be used." Here in the United States, we're always interested in having more information, more is better, but we don't want someone to tell us exactly how to use that information in a prescriptive way.
This transcript has been lightly edited for clarity.
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Latest Advances and Updates of Treatment in the Real World at AUA
May 1st 2024The annual meeting of the American Urological Association (AUA) not only presents the newest therapies coming out but showcases the latest in how treatments are being used in the real world, said Stephen Freedland, MD, of Cedars Sinai.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Diving Deep Into Specialty Pharmacy: Insights and Forecasts From IQVIA’s Doug Long
May 1st 2024Doug Long, MBA, vice president of industry relations at IQVIA, covered a bevy of stakeholder investment–related topics in his presentation at AXS24 on trends in specialty pharmacy, chief among them challenges facing the industry, obesity medications, generics and biosimilars, new product launches, and the outlook for the US market.
Read More
AUA to Focus on Inclusive Care, Robotic Surgeries, and Future of Urology at 2024 Annual Meeting
May 1st 2024The American Urological Association (AUA) 2024 Annual Meeting will highlight the latest innovations and future trends in urology, featuring dynamic plenary sessions, educational opportunities for providers, and discussions on cutting-edge treatments and global health initiatives.
Read More